EvoclinTreatment for Acne
Connetics' New Drug Application for Actiza Has Been Accepted For Filing by the FDA
PALO ALTO, Calif., March 4, 2004 -- Connetics Corporation (Nasdaq: CNCT), a specialty pharmaceutical company focused on dermatology, today announced that it has received confirmation that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Actiza, as of December 24, 2003. Actiza is an investigational new drug formulation of 1% clindamycin delivered in the Company's proprietary VersaFoam(TM) delivery system, as a potential new topical treatment for acne.
Connetics Corporation is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market. The Company's marketed products are OLUX (clobetasol propionate) Foam, 0.05% and Luxiq (betamethasone valerate) Foam, 0.12%. Connetics is developing Extina, a foam formulation of the antifungal drug ketoconazole, Actiza, a foam formulation of clindamycin for treating acne, and Velac Gel, a combination of clindamycin and tretinoin for treating acne. Connetics has branded its innovative foam drug delivery vehicle VersaFoam(TM). These formulations aim to improve the management of dermatological diseases and provide significant product differentiation, and have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance. For more information about Connetics and its products, please visit www.connetics.com
Source: Connetics Corporation
Posted: March 2004
- Evoclin Connetics Corporation - Treatment for Acne - October 22, 2004